| Summary: | One goal of atrial fibrillation treatment is to prevent complication of
thromboemboli using warfarin anticoagulant. Warfarin can reduce stroke risk, but it increases bleeding risk than control therapy. To obtain desirable therapeutic effects and minimize bleeding risk, strict control of patients INR needs to do. The goal of research was to give illustration of therapeutic length to reach INR target and side effects of drug in initial dosage use of 3 and 5 mg warfarin on AF patient.
Experimental research using data collection technique was conducted
prospectively in 20 patients to compare therapeutic length to reach INR target and side effects of drug in AF patients after giving 3 and 5 mg warfarin, from July 2011 to November 2011.
Results of laboratory examination, therapeutic length (day) to reach INR
target of 5 mg warfarin dosage groups were 3rd day (1 patient), 4th day (5
patients), 5th day (4 patients), respectively and 3 mg warfarin dosage groups were 4th day (1 patient), 5th day (4 patients), 6th Therapeutic length to reach INR target of 5 mg warfarin dosage groups was 4,30 ± 0,21 day, than 3 mg warfarin 5,40 ± 0,22 day (p < 0.05). Side effects of bleeding such as blackish feces occurred in 1 (of 10 patients) of 5 mg warfarin dosage groups
|
|---|